Dean Welsch, PhD
CEO
ImmunoMet Therapeutics
Dr. Welsch has over 35 years of experience in pharmaceutical research and development, including having led programs in oncology, inflammation, allergy & respiratory, and cardiovascular disease. His expertise includes aspects of drug development from identification of novel drug targets through completion of Phase IIa clinical proof-of-concept studies. Prior to joining ImmunoMet Therapeutics in 2020, Dr. Welsch served as Vice President of Biology at Peloton Therapeutics before being purchased by Merck. Before that he was Executive Director of Translation Sciences at BioMed Valley Discoveries, where he led their first-in-class ERK inhibitor program to clinical PoC. His career includes 20+ years with Pfizer and legacy companies where he was a Science Fellow and Executive Director.
Dr. Welsch received a BS in Chemistry from Hope College, a PhD in Biochemistry from the University of Minnesota in the lab of Dr. G. Nelsestuen, and completed his post-doctoral training with Dr. P. Friedman at Merck Research Labs. He has co-authored more than 35 peer-reviewed publications and is a co-inventor on multiple patents.
Sessions
-
23-Jun-2026Theater 3ImmunoMet Therapeutics
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}